Express Scripts Picks AbbVie HCV Drugs Over Gilead

By | December 22, 2014

Scalper1 News

Pharmacy benefit manager Express Scripts (ESRX) announced Monday that it’s putting AbbVie’s newly approved hepatitis C treatment on its preferred formulary list and knocking off Gilead Sciences’ rivals. Gilead plunged 13% in morning trading in the stock market today, and AbbVie (ABBV) was down nearly 1%. Late Friday, the FDA approved Viekira Pak, a combination of three novel drugs along with an older product called ritonavir, as the second Scalper1 News

Scalper1 News